Drug Trial Radar · NCT06990269
Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
240
Planned (sponsor's estimate)
Start
Nov 10, 2025
Primary completion
Feb 28, 2030
Study completion Aug 30, 2030
Sponsor
- Lead sponsor
- ADARx Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 25, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 2 study is designed to assess the efficacy of ADX-038 compared with placebo in participants with GA secondary to AMD. Safety, pharmacokinetics (PK), and pharmacodynamics (PD) will also be assessed.
Conditions
- Geographic Atrophy Secondary to Age-related Macular Degeneration
Interventions
ADX-038Drug
siRNA duplex oligonucleotide
PlaceboDrug
Saline
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate the effect of ADX-038 on the preservation of the EZ layerTime frame: 12 months
Locations
83 sites in 12 countries. Site status is shown where the registry gives one.
ADARx Clinical Site
Gilbert, Arizona · Recruiting
ADARx Clinical Site
Phoenix, Arizona · Recruiting
ADARx Clinical Site
Bakersfield, California · Recruiting
ADARx Clinical Site
Beverly Hills, California · Recruiting
ADARx Clinical Site
Huntington Beach, California · Recruiting
ADARx Clinical Site
Poway, California · Recruiting
ADARx Clinical Site
Riverside, California · Recruiting
ADARx Clinical Site
Walnut Creek, California · Recruiting
ADARx Clinical Site
Orlando, Florida · Recruiting
ADARx Clinical Site
Wildwood, Florida · Recruiting
ADARx Clinical Site
Hagerstown, Maryland · Recruiting
ADARx Clinical Site
Reno, Nevada · Recruiting
ADARx Clinical Site
Erie, Pennsylvania · Withdrawn
ADARx Clinical Site
Austin, Texas · Recruiting
ADARx Clinical Site
Bellaire, Texas · Recruiting
ADARx Clinical Site
Dallas, Texas · Recruiting
ADARx Clinical Site
McAllen, Texas · Recruiting
ADARx Clinical Site
Round Rock, Texas · Recruiting
ADARx Clinical Site
San Antonio, Texas · Recruiting
ADARx Clinical Site
The Woodlands, Texas · Recruiting
ADARx Clinical Site
St. George, Utah · Recruiting
ADARx Clinical Site
Malvern, Australia · Recruiting
ADARx Clinical Site
Sydney, Australia · Recruiting
ADARx Clinical Site
Albury, New South Wales, Australia · Recruiting
ADARx Clinical Site
Hurstville, New South Wales, Australia · Recruiting
ADARx Clinical Site
Parramatta, New South Wales, Australia · Recruiting
ADARx Clinical Site
Sutherland, New South Wales, Australia · Recruiting
ADARx Clinical Site
Sydney, New South Wales, Australia · Recruiting
ADARx Clinical Site
East Melbourne, Victoria, Australia · Recruiting
ADARx Clinical Site
Rowville, Victoria, Australia · Recruiting
ADARx Clinical Site
Vienna, Austria · Not yet recruiting
ADARx Clinical Site
Vienna, Austria · Not yet recruiting
ADARx Clinical Site
Graz, Styria, Austria · Not yet recruiting
ADARx Clinical Site
Innsbruck, Tyrol, Austria · Not yet recruiting
ADARx Clinical Site
Edmonton, Alberta, Canada · Not yet recruiting
ADARx Clinical Site
Vancouver, British Columbia, Canada · Recruiting
ADARx Clinical Site
Vancouver, British Columbia, Canada · Recruiting
ADARx Clinical Site
London, Ontario, Canada · Not yet recruiting
ADARx Clinical Site
Ottawa, Ontario, Canada · Recruiting
ADARx Clinical Site
Ottawa, Ontario, Canada · Recruiting
Showing 40 of 83 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.